Clinical Trials Logo

Gaucher Disease clinical trials

View clinical trials related to Gaucher Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06258577 Not yet recruiting - Gaucher Disease Clinical Trials

Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency

Start date: May 1, 2024
Phase:
Study type: Observational

High-risk screening for Gaucher disease and Acid Sphingomyelinase Deficiency in patients with splenomegaly and/or thrombocytopenia in Taiwan

NCT ID: NCT05816993 Not yet recruiting - Gaucher Disease Clinical Trials

Assessment of Neurological Manifestations in Gaucher Disease Patients

Start date: April 20, 2023
Phase:
Study type: Observational

The current work aims to detect the frequency and types of neurological disorders in patient diagnosed as Gaucher disease in Assiut University Children's Hospital

NCT ID: NCT05669729 Not yet recruiting - Gaucher Disease Clinical Trials

A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion

Start date: March 3, 2025
Phase:
Study type: Observational

The main purpose of this survey is to determine participants', caregivers', and nurses' understanding and use of educational materials (EM) on VPRIV home treatment. EM includes an infusion diary and guide and an emergency plan related to VPRIV infusion given at home for Gaucher disease. The survey is conducted in European countries. Data will be collected directly from participants, caregivers, and nurses in form of a questionnaire, electronic or paper.

NCT ID: NCT03590548 Not yet recruiting - Gaucher Disease Clinical Trials

Clinical Audit of Managment of Gausher Disease in Children

Start date: July 2018
Phase:
Study type: Observational [Patient Registry]

clinical audit on managment of gausher disease in children

NCT ID: NCT01898325 Not yet recruiting - Fibrosis Clinical Trials

Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan

Start date: August 2013
Phase: N/A
Study type: Interventional

The investigated cohort will examine liver and spleen fibrosis in patients with Gaucher disease divided into two groups, naive GD patients and GD patients treated with ERT. As liver biopsy in these patients not recommended because the risk of bleeding using Fibroscan is a safe with diagnostic accuracy regarding the liver (& Spleen) fibrosis. Estimating spleen fibrosis is an innovative approach in liver disease and Gaucher. The evaluation of fibrosis with this new and safe method could avoid complications antiinvasive procedure in GD patients. The addition of fibrosis biomarkers will help for patients score evaluation. The finding of liver and spleen stiffness will be evaluated in native and ERT treated Gaucher patients in order to assess ERT effect on fibrosis. The Aims are: 1) To assess liver and spleen stiffness measurement using fibroscan and evaluate liver and spleen fibrosis in patients with GD. 2) To compare the elastography in two cohorts of GD patients: ERT treated and naïve GD patients and two control groups of patients: healthy and Non Alcoholic Steatohepatitis (NASH) patients. 3) To correlate the elastography findings with clinical and laboratory data in the four patient groups focusing on Gaucher disease manifestations and GD severity. To compare the elastography in GD naïve and ERT treated patients.